top of page

Drug-Resistant TB Trial Results Published in New England Journal of Medicine

The results of ZeNix, a Phase 3 clinical trial that took place in 11 sites across Georgia, Moldova, Russia, and South Africa, revealed that the BPaL treatment remains effective against highly drug-resistant strains of tuberculosis (TB) with reduced dosage and/or duration of the linezolid component of the regimen.1 Along with the maintenance of efficacy, there was a decrease in linezolid-associated side effects that accompanied the reduced dosage or duration of linezolid.1 The results from the trial, which was led by TB Alliance, a non-profit TB drug developer, were published today in the New England Journal of Medicine. Read more here.

93 views0 comments

Recent Posts

See All

The Stop TB Partnership today is releasing the campaign toolkit for this year’s World TB Day, 24 March 2023 Yes! We Can End TB. The theme brings attention toTB and our collective power to end TB by 20

TAG has released its Pipeline Report regarding TB Treatment updates and results from trials completed in 2022 written by Lindsay McKenna. Read the report here!

bottom of page